News Release

The Dai-ichi Life Insurance Company, Limited
13-1, Yurakucho 1-chome, Chiyoda-ku,
Tokyo 100-8411, Japan
http://www.dai-ichi-life.co.jp/english/



May 13, 2020

Dai-ichi Life to Impact Invest in Modulus Discovery, Inc.

- Contributing to Realizing Accessible Healthcare for All by Cutting Development Timelines and Costs of Pharmaceuticals -

The Dai-ichi Life Insurance Company, Limited (the "Company"; President and Representative Director: Seiji Inagaki) has decided to impact invest¹ JPY200 million in Modulus Discovery, Inc. ("Modulus"; CEO: S. Roy Kimura, Ph.D.; COO: Kazuki Ohno, Dr.Eng.), a Japanese startup engaged in drug development based on computational chemistry. This impact investment is a part of the Company's ESG investment program.



- A startup engaged in small molecule drug development based on computational chemistry.
- The use of computational chemistry in drug discovery can cut development timelines and lead to substantial reductions in development costs through fewer experiments and other efficiencies, thereby enabling innovative new drug development.



Social Impact

Realizing Accessible Healthcare for All Realize highly accessible healthcare even in developing countries by supplying inexpensive drugs at an early stage through efficient research and development of new drugs.



The Company will provide capital support to Modulus' initiatives as it expects this investment will realize high level of returns as well as highly accessible healthcare for all (social impact). The Company will also continuously monitor progress.

The Company will continue to enhance investment returns through increasingly sophisticated and diverse investment methods. As a responsible institutional investor that should contribute toward realizing a sustainable society, the Company is also actively engaged in ESG investment.

¹ Impact investment is an investment method where Dai-ichi Life makes investment decisions with the intent to gain investment returns and generate social impacts (e.g., structural change in society).

Modulus CEO S. Roy Kimura, Ph.D. made the following remarks:



Today, medical costs have grown tremendously, becoming a serious social problem around the world. Rising drug prices have been cited as one reason for the high costs. With the aging of populations, the number of patients suffering from cancer and other chronic diseases has increased. Meanwhile, the R&D costs required for advances in regenerative medicine, macromolecular drugs and other areas have been increasing dramatically, and these costs are becoming unsustainable. Notably, small molecule therapeutics have promising features such as low manufacturing costs, applicability to a wide range of diseases and good potential for development into oral medicines.

Modulus is working to dramatically streamline the drug discovery process by combining cutting-edge disease biology insights, sophisticated computational science and technology and a global network-based research operating model where institutions around the world collaborate each other. Through these efforts, Modulus has created many new small molecule drug candidates from its proprietary pipeline. In addition, Modulus will contribute to the development of Japan's innovation ecosystem by linking world-class Japanese academic research and the pharmaceutical industry. In doing so, Modulus aims to deliver innovations from Japan that have a large impact on healthcare around the world.

Company Outline

Trade Name	Modulus Discovery, Inc.
Head Office	5 th KS Floor, Risona Kudan Bldg., 1-5-6, Kudan-Minami, Chiyoda-ku, Tokyo
Representative	S. Roy Kimura, Ph.D.(CEO), Kazuki Ohno, Dr.Eng. (COO)
Established	August 2016
Business	Developing small molecule drugs by combining cutting-edge disease biology insights,
Description	computational science and structural analysis.

Dai-ichi Life's Impact Investment History

Headline	Release Date	URL
Dai-ichi Life to Engage in Impact Investment —First Impact Investment in Gojo & Company, Inc. which provides support for micro-finance business—	Oct. 23, 2017	https://www.dai-ichi- life.co.jp/english/news_release/2017/ pdf/index_012.pdf
Dai-ichi Life to Invest in Spiber Inc. —Second Impact Investment through Support for Development of New-Generation Bio-Materials—	Oct. 23, 2017	https://www.dai-ichi- life.co.jp/company/news/pdf/2017_04 4.pdf
Dai-ichi Life to Invest in CureApp, Inc. —Third Impact Investment through Support for Smoking Cessation Treatment Applications—	Feb. 26, 2018	https://www.dai-ichi- life.co.jp/english/news_release/2017/ pdf/index_018.pdf
Dai-ichi Life to Impact Invest in CROWD CREDIT, Inc. —Energize Business Activities in Developing Countries to Alleviate the Global Supply-Demand Gap for Funds—	Apr. 5, 2018	https://www.dai-ichi- life.co.jp/company/news/pdf/2018_00 2.pdf

Dai-ichi Life to Impact Invest in SUSMED, Inc. —Promote the Widespread Adoption of Non-Drug Therapies through Insomnia Therapy Apps—	Jun. 4, 2018	https://www.dai-ichi- life.co.jp/company/news/pdf/2018_00 8.pdf
Dai-ichi Life to Impact Invest in MELTIN MMI —Mitigating Accidents Caused by Work in Hazardous Environments Using MELTIN's Avatar Robots—	Oct. 17, 2018	https://www.dai-ichi- life.co.jp/english/news_release/2018/ pdf/index_004.pdf
Dai-ichi Life to Impact Invest in MOLCURE Inc. —Shortening Pharmaceutical Development with the World's First Antibody Discovery Platform Utilizing AI—	Nov. 27, 2018	https://www.dai-ichi- life.co.jp/english/news_release/2018/ pdf/index_007.pdf
Dai-ichi Life to Impact Invest in QD Laser, Inc. —World's First Eyewear that Employs State-of-the-Art Laser Technology Improves Quality of Life for Low-Vision Patients—	Dec. 12, 2018	https://www.dai-ichi- life.co.jp/english/news_release/2018/ pdf/index_010.pdf
Dai-ichi Life to Impact Invest in Challenergy Inc. —Helping to reduce CO2 emissions using the world's first wind turbine capable of generating electricity even in typhoons—	Feb. 28, 2019	https://www.dai-ichi- life.co.jp/english/news_release/2018/ pdf/index_012.pdf
Dai-ichi Life to Impact Invest in Venture Fund managed by Energy & Environment Investment, Inc. —Japan's Only Independent Venture Capital Focused on the Energy and Resource Related Sectors—	Mar. 20, 2019	https://www.dai-ichi- life.co.jp/english/news_release/2018/ pdf/index_015.pdf
Impact Investment in CureApp and NeuroTrack —Extending healthy life expectancy and improve quality of life through synergies between investments and life insurance—	Jul. 5, 2019	https://www.dai-ichi- life.co.jp/english/news_release/2019/ pdf/index_008.pdf
Dai-ichi Life to Impact Invest in Integral Geometry Science —Contributing to a reduction in breast cancer deaths through the world's first high precision breast cancer vizualizing system—	Sep. 13, 2019	https://www.dai-ichi- life.co.jp/english/news_release/2019/ pdf/index_015.pdf
Dai-ichi Life to Impact Invest in UniFa —Contributing to Resolving the Lengthy Daycare Waiting List Problem Caused by a Shortage of Nursery Care Workers by Introducing IoT and AI to Daycare Operations—	Sep. 27, 2019	https://www.dai-ichi- life.co.jp/english/news_release/2019/ pdf/index_014.pdf
Dai-ichi Life to Impact Invest in Life is Tech, Inc. —Contributing to Solving the IT Talent Shortage with IT and Programming Education Services—	Nov. 11, 2019	https://www.dai- ichilife.co.jp/english/news_release/20 19/pdf/index_018.pdf
Dai-ichi Life to Impact Invest in World's First Anti-Smoking Social Impact Bond - Support Social Impact Creator and Investment Recipient CureApp, through Investment in Anti-Smoking Project -	Nov. 29, 2019	https://www.dai-ichi- life.co.jp/english/news_release/2019/ pdf/index_021.pdf